Archives

Joyvest demonstration

Have you heard of the Joyvest by Lyckna? It’s an activity vest that plays music when you move! Carina, from the Huntington’s Disease Association (RHS) in Sweden makes a demonstration. […]

uniQure announced they are resuming the patient enrollment at the higher-dose level in AMT-130 trial

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

2022 Latin American Huntington’s Disease Conference

The 2022 Huntington’s Disease (HD) Latin American Conference brings together leading international representatives of the HD community – clinicians, scientists, social workers, students, family associations, affected individuals, and at-risk youth. […]

MENA Organization for Rare Diseases Annual Meeting 2023

MENA Organization for Rare Diseases Annual Meeting will take place in Dubai from 3 to 5 March 2023. During this meeting, experts will deliver the most updated knowledge in presentations […]

Online Conversation – Explore for Huntington with Dimitri Poffé

Do you know Dimitri Poffé? Join us on Thursday 14 July at 19:00 h (CET) for a talk with him. This conversation will be held entirely in Spanish via Zoom, […]

uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Annexon Biosciences updates trial results

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

HDYO Young Adults Congress

After moving completely virtual, HDYO is excited to host their first ever in person conference for young adults, families and professionals impacted by Huntington’s disease. They are finalizing details, but […]

EHDN 2022 Plenary Meeting

Topics presented during the EHDN2022 Plenary Meeting will contain reports on recent advances in HD research (in both basic and clinical sciences). Aside from participating in the plenary and other […]